For investors

New Users Drive Treatment Opportunities

The potential of ECMO therapies

Extracorporeal Life Support Systems (ECLS) are modified heart-lung machines that can be used to temporarily support or replace heart and lung function in patients with acute respiratory or circulatory failure – about 2.2 million patients with this condition are potentially eligible for this treatment worldwide every year.

ECLS technologies were once considered a last resort. But that is changing: A new generation of clinical users is utilizing the devices in emerging therapy options for an entirely new range of patient conditions and indications – like Sudden Cardiac Arrest (CA) or  Chronic Obstructive Pulmonary Disease (COPD). And the numbers are rising dramatically.

These new approaches to healthcare called for a new take on technology. So we reexamined ECLS from a different perspective, redesigned the technology from the ground up, and manufactured cutting-edge equipment to fuel these healthcare developments. 

Our devices have the potential to save lives and improve healthcare because they are:

Simple.

User-friendly equipment helps clinicians focus on patients instead of tools.

Straightforward design facilitates treatment safety to improve outcomes – also in emergency situations.

Easy operation has a direct impact on the time and effort needed for training.

Mobile.

Compact size aids patient transport in severely restricted spaces within hospitals, between clinics, or even in the field*.

Flexible placement facilitates patient mobilization – a critical parameter for ECMO.

Adaptable setup enables use in diverse treatment situations.

Reliable.

Optimized construction maximizes performance to minimize side effects.

Premium components provide long-term stability, wear behavior, and effectiveness.

Safe operation is ensured by design – with mechanical robustness, full device integration, and automatic safety measures.

*Current products intended to be used in professional healthcare environment only.

HEMOVENT PRODUCTS ARE NOT CLEARED OR APPROVED BY THE
U.S. FOOD AND DRUG ADMINISTRATION AND ARE NOT AVAILABLE FOR SALE IN THE U.S.